Applied Therapeutics (APLT) Stock Forecast, Price Target & Predictions
APLT Stock Forecast
Applied Therapeutics stock forecast is as follows: an average price target of $4.50 (represents a 309.09% upside from APLT’s last price of $1.10) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
APLT Price Target
The average price target for Applied Therapeutics (APLT) is $4.50 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $4.00. This represents a potential 309.09% upside from APLT's last price of $1.10.
APLT Analyst Ratings
According to 5 Wall Street analysts, Applied Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for APLT stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Applied Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 29, 2024 | Brian Skorney | Robert W. Baird | $5.00 | $9.41 | -46.89% | 354.55% |
| Nov 29, 2024 | Brian Abrahams | RBC Capital | $4.00 | $9.41 | -57.51% | 263.64% |
The latest Applied Therapeutics stock forecast, released on Nov 29, 2024 by Brian Skorney from Robert W. Baird, set a price target of $5.00, which represents a -46.89% decrease from the stock price at the time of the forecast ($9.41), and a 354.55% increase from APLT last price ($1.10).
Applied Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 2 | 2 |
| Avg Price Target | $4.50 | $4.50 | $4.50 |
| Last Closing Price | $1.10 | $1.10 | $1.10 |
| Upside/Downside | 309.09% | 309.09% | 309.09% |
In the current month, the average price target of Applied Therapeutics stock is $4.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 309.09% increase as opposed to Applied Therapeutics's last price of $1.10. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 29, 2024 | RBC Capital | Outperform | Sector Perform | Downgrade |
| Sep 19, 2024 | Citigroup | Buy | Buy | Hold |
| Aug 27, 2024 | Citigroup | Buy | Buy | Hold |
| Jul 31, 2024 | William Blair | Outperform | Initialise | |
| Mar 25, 2024 | RBC Capital | Outperform | Initialise | |
| Aug 16, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
| Aug 16, 2022 | Wells Fargo | Overweight | Overweight | Hold |
Applied Therapeutics's last stock rating was published by RBC Capital on Nov 29, 2024. The company Downgrade its APLT rating from "Outperform" to "Sector Perform".
Applied Therapeutics Financial Forecast
Applied Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $30.71M | $22.76M | $15.04M | $9.20M | $3.24M | $974.55K | $904.25K | $11.76M | $511.67K | $75.00K | $2.50M | $3.33M | $8.00M | $20.00M |
| High Forecast | $64.58M | $47.86M | $31.63M | $19.35M | $6.82M | $2.05M | $1.90M | $21.53M | $1.08M | $157.69K | $5.26M | $3.33M | $16.82M | $42.05M |
| Low Forecast | $5.95M | $4.41M | $2.91M | $1.78M | $627.73K | $188.73K | $175.12K | $1.98M | $99.09K | $14.52K | $484.15K | $3.33M | $1.55M | $3.87M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Applied Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. APLT's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Applied Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-15.49M | $-17.18M |
| Avg Forecast | $18.43M | $13.66M | $9.03M | $5.52M | $1.94M | $584.73K | $542.55K | $7.05M | $307.00K | $45.00K | $1.50M | $2.00M | $4.80M | $12.00M |
| High Forecast | $38.75M | $28.72M | $18.98M | $11.61M | $4.09M | $1.23M | $1.14M | $12.92M | $645.50K | $94.62K | $3.15M | $2.00M | $10.09M | $25.23M |
| Low Forecast | $3.57M | $2.65M | $1.75M | $1.07M | $376.64K | $113.24K | $105.07K | $1.19M | $59.45K | $8.71K | $290.49K | $2.00M | $929.57K | $2.32M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -3.23% | -1.43% |
undefined analysts predict APLT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Applied Therapeutics's previous annual EBITDA (undefined) of $NaN.
Applied Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-42.37M | $-29.58M |
| Avg Forecast | $-232.40K | $-837.21K | $-1.48M | $-2.06M | $-2.13M | $-2.31M | $-2.47M | $-1.77M | $-2.84M | $-2.28M | $-2.38M | $-2.30M | $-3.83M | $-4.43M |
| High Forecast | $11.21K | $40.39K | $71.38K | $99.58K | $102.86K | $111.66K | $119.16K | $-1.73M | $-2.37M | $109.99K | $114.69K | $110.99K | $184.84K | $213.50K |
| Low Forecast | $-565.51K | $-2.04M | $-3.60M | $-5.02M | $-5.19M | $-5.63M | $-6.01M | $-1.84M | $-3.31M | $-5.55M | $-5.79M | $-5.60M | $-9.32M | $-10.77M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 11.06% | 6.68% |
Applied Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. APLT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Applied Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $4.71M | $5.29M |
| Avg Forecast | $37.25M | $27.61M | $18.24M | $11.16M | $3.93M | $1.18M | $1.10M | $14.26M | $620.52K | $90.96K | $3.03M | $4.04M | $9.70M | $24.25M |
| High Forecast | $78.32M | $58.05M | $38.36M | $23.46M | $8.27M | $2.49M | $2.31M | $26.11M | $1.30M | $191.24K | $6.37M | $4.04M | $20.40M | $51.00M |
| Low Forecast | $7.21M | $5.35M | $3.53M | $2.16M | $761.28K | $228.88K | $212.37K | $2.41M | $120.17K | $17.61K | $587.15K | $4.04M | $1.88M | $4.70M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.49% | 0.22% |
Applied Therapeutics's average Quarter SG&A projection for Mar 24 is $4.04M, based on 1 Wall Street analysts, with a range of $4.04M to $4.04M. The forecast indicates a -14.17% fall compared to APLT last annual SG&A of $4.71M (Sep 23).
Applied Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.47 | $-0.00 |
| Avg Forecast | $-0.02 | $-0.06 | $-0.10 | $-0.14 | $-0.15 | $-0.16 | $-0.17 | $-0.12 | $-0.20 | $-0.16 | $-0.16 | $-0.16 | $-0.27 | $-0.31 |
| High Forecast | - | - | - | $0.01 | $0.01 | $0.01 | $0.01 | $-0.12 | $-0.16 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 |
| Low Forecast | $-0.04 | $-0.14 | $-0.25 | $-0.35 | $-0.36 | $-0.39 | $-0.42 | $-0.13 | $-0.23 | $-0.38 | $-0.40 | $-0.39 | $-0.65 | $-0.75 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.77% | 0.00% |
According to undefined Wall Street analysts, Applied Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to APLT previous annual EPS of $NaN (undefined).
Applied Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| INAB | IN8bio | $0.29 | $14.00 | 4727.59% | Buy |
| VINC | Vincerx Pharma | $0.19 | $2.00 | 952.63% | Buy |
| STTK | Shattuck Labs | $1.15 | $12.00 | 943.48% | Hold |
| MOLN | Molecular Partners | $5.25 | $29.00 | 452.38% | Buy |
| XFOR | X4 Pharmaceuticals | $0.74 | $3.67 | 395.95% | Buy |
| CCCC | C4 Therapeutics | $4.05 | $20.00 | 393.83% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.31 | $6.00 | 358.02% | Buy |
| GANX | Gain Therapeutics | $1.68 | $7.00 | 316.67% | Buy |
| APLT | Applied Therapeutics | $1.10 | $4.50 | 309.09% | Buy |
| PMVP | PMV Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| BCAB | BioAtla | $1.31 | $5.00 | 281.68% | Buy |
| ACRV | Acrivon Therapeutics | $7.21 | $22.50 | 212.07% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| LYRA | Lyra Therapeutics | $0.18 | $0.50 | 177.78% | Hold |
| TERN | Terns Pharmaceuticals | $6.80 | $18.67 | 174.56% | Buy |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| ORIC | ORIC Pharmaceuticals | $8.25 | $20.00 | 142.42% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
| HOOK | HOOKIPA Pharma | $2.13 | $3.00 | 40.85% | Buy |